# Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

> **NCT03777657** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 997 (actual)

## Conditions studied

- Gastric, or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Placebo
- **DRUG:** Cisplatin
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT03777657
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2023-02-28
- **Final completion:** 2024-08-27
- **Target enrollment:** 997 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03777657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03777657, "Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03777657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*